Syneos eyes ocular trials with new catalyst site network

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dolgachov)
(Image: Getty/dolgachov)
Syneos Health has launched a Catalyst Ophthalmology Site Network to support startup and delivery of ocular clinical trials.

The Ophthalmology Site Network currently includes 24 sites across the US and Europe.

Participation in the network, which is expected to grow to more than 30 sites globally in the coming months, is by invitation only.

According to the Syneos, members have the opportunity to participate in an increased volume of ophthalmology-related trials. Additionally, sites receive a dedicated relationship manager.

The Ophthalmology Site Network also will include fully integrated central institutional review board (IRB) and reading center services.

With the addition of the newest network, the company’s Catalyst Site Program – launched in 2016 – now includes more than 100 sites across the US, UK, and APAC.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more